कृपया अन्य खोज का प्रयास करें
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient’s own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Alan B. Lumsden | - | - | Member of Scientific Advisory Board |
York N. Hsiang | - | 2020 | Member of Scientific Advisory Board |
Peter Alan Lacey | 67 | 2020 | Independent Chairman |
Loran Swanberg | - | 2020 | Independent Director |
Thomas A. Smeenk | 61 | 2019 | Co-Founder, President, CEO & Director |
Norman C. W. Wong | - | 2017 | Member of Scientific Advisory Board |
Kumar L. Hari | - | 2017 | Member of Scientific Advisory Board |
Sheila Copps | - | 2020 | Member of Board of Advisors |
David H. Tsubouchi | 71 | 2020 | Member of Board of Advisors |
Ronnie Allen Hershman | - | 2020 | Independent Director |
Ernst von Schwarz | - | 2022 | Member of Scientific Advisory Board |
Johannes Grillari | - | 2022 | Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है